CureVac N.V. (CVAC)
3.28
-0.01 (-0.30%)
At close: Feb 20, 2025, 3:59 PM
3.28
0.00%
After-hours: Feb 20, 2025, 06:17 PM EST
undefined% (undefined)
| Bid | 3.2 |
| Market Cap | 735.72M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.49 |
| PE Ratio (ttm) | 6.69 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.5 |
| Volume | 423,439 |
| Avg. Volume (20D) | 796,681 |
| Open | 3.38 |
| Previous Close | 3.29 |
| Day's Range | 3.26 - 3.45 |
| 52-Week Range | 2.21 - 5.28 |
| Beta | undefined |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2020
Employees 999
Stock Exchange NASDAQ
Ticker Symbol CVAC
Website https://www.curevac.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CVAC stock is "Hold." The 12-month stock price forecast is $10, which is an increase of 204.88% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
CureVac N.V. is scheduled to release its earnings on Apr 23, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.41%
Shares of vaccine makers are trading higher after ...
Unlock content with
Pro Subscription
1 month ago
+5.41%
Shares of vaccine makers are trading higher after the first bird flu death was reporting in the US. Additionally, a recent DCD report noted an increase in acute respiratory illness activity.
